vs
Side-by-side financial comparison of Abbott Laboratories (ABT) and Cooper Companies (The) (COO). Click either name above to swap in a different company.
Abbott Laboratories is the larger business by last-quarter revenue ($11.5B vs $1.1B, roughly 10.8× Cooper Companies (The)). Abbott Laboratories runs the higher net margin — 15.5% vs 7.9%, a 7.6% gap on every dollar of revenue. On growth, Cooper Companies (The) posted the faster year-over-year revenue change (4.6% vs 4.4%). Abbott Laboratories produced more free cash flow last quarter ($2.6B vs $149.9M). Over the past eight quarters, Abbott Laboratories's revenue compounded faster (7.2% CAGR vs 6.9%).
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.
The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California. The company consists of two business units, CooperVision (CVI) which manufactures contact lenses, and CooperSurgical (CSI), which manufactures medical devices and fertility and genomic products for the women's healthcare market.
ABT vs COO — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $11.5B | $1.1B |
| Net Profit | $1.8B | $84.6M |
| Gross Margin | 57.0% | 61.1% |
| Operating Margin | 19.6% | 13.2% |
| Net Margin | 15.5% | 7.9% |
| Revenue YoY | 4.4% | 4.6% |
| Net Profit YoY | -80.8% | -28.0% |
| EPS (diluted) | $1.01 | $0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.5B | $1.1B | ||
| Q3 25 | $11.4B | $1.1B | ||
| Q2 25 | $11.1B | $1.0B | ||
| Q1 25 | $10.4B | $964.7M | ||
| Q4 24 | $11.0B | $1.0B | ||
| Q3 24 | $10.6B | $1.0B | ||
| Q2 24 | $10.4B | $942.6M | ||
| Q1 24 | $10.0B | $931.6M |
| Q4 25 | $1.8B | $84.6M | ||
| Q3 25 | $1.6B | $98.3M | ||
| Q2 25 | $1.8B | $87.7M | ||
| Q1 25 | $1.3B | $104.3M | ||
| Q4 24 | $9.2B | $117.5M | ||
| Q3 24 | $1.6B | $104.7M | ||
| Q2 24 | $1.3B | $88.9M | ||
| Q1 24 | $1.2B | $81.2M |
| Q4 25 | 57.0% | 61.1% | ||
| Q3 25 | 55.4% | 65.3% | ||
| Q2 25 | 56.4% | 67.8% | ||
| Q1 25 | 56.9% | 68.4% | ||
| Q4 24 | 55.0% | 66.5% | ||
| Q3 24 | 55.8% | 66.1% | ||
| Q2 24 | 55.6% | 67.0% | ||
| Q1 24 | 55.2% | 67.0% |
| Q4 25 | 19.6% | 13.2% | ||
| Q3 25 | 18.1% | 16.6% | ||
| Q2 25 | 18.4% | 18.4% | ||
| Q1 25 | 16.3% | 18.9% | ||
| Q4 24 | 17.4% | 19.5% | ||
| Q3 24 | 17.5% | 19.2% | ||
| Q2 24 | 16.1% | 17.2% | ||
| Q1 24 | 13.9% | 16.4% |
| Q4 25 | 15.5% | 7.9% | ||
| Q3 25 | 14.5% | 9.3% | ||
| Q2 25 | 16.0% | 8.7% | ||
| Q1 25 | 12.8% | 10.8% | ||
| Q4 24 | 84.1% | 11.5% | ||
| Q3 24 | 15.5% | 10.4% | ||
| Q2 24 | 12.5% | 9.4% | ||
| Q1 24 | 12.3% | 8.7% |
| Q4 25 | $1.01 | $0.42 | ||
| Q3 25 | $0.94 | $0.49 | ||
| Q2 25 | $1.01 | $0.44 | ||
| Q1 25 | $0.76 | $0.52 | ||
| Q4 24 | $5.26 | $0.59 | ||
| Q3 24 | $0.94 | $0.52 | ||
| Q2 24 | $0.74 | $0.44 | ||
| Q1 24 | $0.70 | $0.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.9B | $110.6M |
| Total DebtLower is stronger | $12.9B | $2.5B |
| Stockholders' EquityBook value | $52.1B | $8.2B |
| Total Assets | $86.7B | $12.4B |
| Debt / EquityLower = less leverage | 0.25× | 0.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.9B | $110.6M | ||
| Q3 25 | $7.7B | $124.9M | ||
| Q2 25 | $7.3B | $116.2M | ||
| Q1 25 | $6.8B | $100.9M | ||
| Q4 24 | $8.0B | $107.6M | ||
| Q3 24 | $7.8B | $109.7M | ||
| Q2 24 | $7.2B | $112.4M | ||
| Q1 24 | $6.7B | $135.2M |
| Q4 25 | $12.9B | $2.5B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | $14.1B | $2.6B | ||
| Q3 24 | — | $2.6B | ||
| Q2 24 | — | $2.7B | ||
| Q1 24 | — | $2.7B |
| Q4 25 | $52.1B | $8.2B | ||
| Q3 25 | $51.0B | $8.4B | ||
| Q2 25 | $50.6B | $8.3B | ||
| Q1 25 | $48.8B | $8.1B | ||
| Q4 24 | $47.7B | $8.1B | ||
| Q3 24 | $39.8B | $7.9B | ||
| Q2 24 | $39.3B | $7.8B | ||
| Q1 24 | $38.8B | $7.7B |
| Q4 25 | $86.7B | $12.4B | ||
| Q3 25 | $84.2B | $12.4B | ||
| Q2 25 | $84.0B | $12.4B | ||
| Q1 25 | $81.4B | $12.2B | ||
| Q4 24 | $81.4B | $12.3B | ||
| Q3 24 | $74.4B | $12.1B | ||
| Q2 24 | $73.0B | $12.0B | ||
| Q1 24 | $72.5B | $12.0B |
| Q4 25 | 0.25× | 0.30× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.30× | ||
| Q1 25 | — | 0.31× | ||
| Q4 24 | 0.30× | 0.32× | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.35× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.3B | $247.9M |
| Free Cash FlowOCF − Capex | $2.6B | $149.9M |
| FCF MarginFCF / Revenue | 22.9% | 14.1% |
| Capex IntensityCapex / Revenue | 6.0% | 9.2% |
| Cash ConversionOCF / Net Profit | 1.87× | 2.93× |
| TTM Free Cash FlowTrailing 4 quarters | $7.4B | $433.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.3B | $247.9M | ||
| Q3 25 | $2.8B | $261.4M | ||
| Q2 25 | $2.0B | $96.2M | ||
| Q1 25 | $1.4B | $190.6M | ||
| Q4 24 | $2.9B | $268.1M | ||
| Q3 24 | $2.7B | $207.5M | ||
| Q2 24 | $2.0B | $111.0M | ||
| Q1 24 | $1.0B | $122.7M |
| Q4 25 | $2.6B | $149.9M | ||
| Q3 25 | $2.3B | $164.5M | ||
| Q2 25 | $1.5B | $18.1M | ||
| Q1 25 | $933.0M | $101.2M | ||
| Q4 24 | $2.1B | $128.1M | ||
| Q3 24 | $2.1B | $118.5M | ||
| Q2 24 | $1.4B | $36.9M | ||
| Q1 24 | $627.0M | $4.6M |
| Q4 25 | 22.9% | 14.1% | ||
| Q3 25 | 20.2% | 15.5% | ||
| Q2 25 | 13.9% | 1.8% | ||
| Q1 25 | 9.0% | 10.5% | ||
| Q4 24 | 19.6% | 12.6% | ||
| Q3 24 | 20.2% | 11.8% | ||
| Q2 24 | 13.8% | 3.9% | ||
| Q1 24 | 6.3% | 0.5% |
| Q4 25 | 6.0% | 9.2% | ||
| Q3 25 | 4.4% | 9.1% | ||
| Q2 25 | 4.5% | 7.8% | ||
| Q1 25 | 4.7% | 9.3% | ||
| Q4 24 | 6.6% | 13.7% | ||
| Q3 24 | 5.2% | 8.9% | ||
| Q2 24 | 5.1% | 7.9% | ||
| Q1 24 | 4.0% | 12.7% |
| Q4 25 | 1.87× | 2.93× | ||
| Q3 25 | 1.70× | 2.66× | ||
| Q2 25 | 1.15× | 1.10× | ||
| Q1 25 | 1.07× | 1.83× | ||
| Q4 24 | 0.31× | 2.28× | ||
| Q3 24 | 1.64× | 1.98× | ||
| Q2 24 | 1.51× | 1.25× | ||
| Q1 24 | 0.84× | 1.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABT
Segment breakdown not available.
COO
| Sphere Other | $365.0M | 34% |
| Toric And Multifocal | $344.7M | 32% |
| Office And Surgical | $214.5M | 20% |
| Fertility | $140.9M | 13% |
